【摘要】 近年来对抑郁症发病机制和药物治疗靶标的研究取得了很大进展,围绕神经可塑性、神经发生、下丘脑-垂体-肾上腺(HPA)轴等后续神经系统适应性改变以及免疫系统变化,确定了谷氨酸受体、神经肽受体、糖皮质激素受体、褪黑激素受体和细胞因子受体等抗抑郁药物作用的新靶标。目前,已发现大量具有抗抑郁作用的新化合物,褪黑激素受体激动剂阿戈美拉丁、促肾上腺皮质激素释放激素受体拮抗剂喹硫平已经上市,神经激肽2受体拮抗剂沙瑞度坦、糖皮质激素受体拮抗剂米非司酮正在进行Ⅲ期临床研究,10余个药物进入临床研究阶段。本文对近5年新型抗抑郁药物的研究进展进行简要综述。更多还原

【Abstract】 With an increasing knowledge,neurotrophic hypothesis and cytokine hypothesis,neuroplasticity,hippocampus-neurogenesis,HPA axis and immune system are included in the pathogenesis of depression,which might be the antidepressant targets.Several potential therapeutic targets have been identified for the disease,such as glutamic acid receptors,neuropeptide receptors,glucocorticoid receptors,melatonin receptors and cytokine receptors.With the development of understanding the new drug targets of depression,the research on new depressive drugs becomes a new research hotspot.A lot of novel antidepressive compounds have been designed and synthesized;more than ten of them are currently used in clinic or in advanced clinical trials.The mlatonin receptor agonist agomelatine and the corticotrophin releasing hormone receptor antagonist quetiapine have been approved as new antidepressive drugs.Mifepristone and saredutant,as a glucocorticoid receptor antagonist and a neurokinin 2 receptor antagonist,are in phase III clinical trials.Advances in the development of novel depressive targets and drugs in recent 5 years are discussed in the paper.更多还原